Company intelligence / Profile preview

Aurora Biosynthetics

Sydney, New South Wales, Australia

Ownership: Private
Development stage: Other

Overview

Aurora Biosynthetics launched in 2024 as a subsidiary of Myeloid Therapeutics, providing GMP manufacturing of RNA therapeutics components (pDNA, mRNA, LNPs) and fill-finish services for both clinical and commercial clients. It does not develop its own therapeutics—there are no clinical trial results, as it is a contract/generic manufacturer—and was created to access and scale advanced RNA manufacturing in Asia-Pacific as part of a public-private initiative.

Modalities: mRNA-based drugsDNA vaccineLipid nanoparticle delivery therapyPlasmid DNA
Industry: Contract Manufacturing Organization

Partnerships

New South Wales (NSW) GovernmentRNA AustraliaMacquarie University

Beyond the preview

Go deeper on Aurora Biosynthetics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aurora Biosynthetics.

Explore the full profile